PCSK9i reduces plaque burden in coronary arteries - PACE-CME

PCSKi reduces plaque burden in coronary arteries

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

A positive view on a negative trial with DOAC after TAVR
A positive view on a negative trial with DOAC after TAVR
ACC.22
A positive view on a negative trial with DOAC after TAVR
- Megan Coylewright, MD
A first clinical trial testing the use of an H₂S donor after heart attack
A first clinical trial testing the use of an H₂S donor after heart attack
ACC.22
A first clinical trial testing the use of an H₂S donor after heart attack
- Marie-Sophie de Koning, MD
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
ACC.22
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
- Florian Rader, MD
Beginning of an era: Treatment of elevated Lp(a)
Beginning of an era: Treatment of elevated Lp(a)
ACC.22
Beginning of an era: Treatment of elevated Lp(a)
- Steven Nissen, MD